Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

ASC30

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity

Ascletis Pharma (China) Co · Phase 1/2 · Completed · Enrollment 115

NCT06679959

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
SAD Cohort 1n/rn/rn/rn/r
SAD Cohort 2n/rn/rn/rn/r
SAD Cohort 3n/rn/rn/rn/r
SAD Cohort 4n/rn/rn/rn/r
SAD Cohort 5n/rn/rn/rn/r
SAD Cohort 6n/rn/rn/rn/r
SAD Cohort 7n/rn/rn/rn/r
SAD Cohort 8n/rn/rn/rn/r
MAD Cohort 1n/rn/rn/rn/r
MAD Cohort 2n/rn/rn/rn/r
MAD Cohort 3n/rn/rn/rn/r

Not shown

  • SAD Cohort 1: endpoint not reported
  • SAD Cohort 2: endpoint not reported
  • SAD Cohort 3: endpoint not reported
  • SAD Cohort 4: endpoint not reported
  • SAD Cohort 5: endpoint not reported
  • SAD Cohort 6: endpoint not reported
  • SAD Cohort 7: endpoint not reported
  • SAD Cohort 8: endpoint not reported
  • MAD Cohort 1: endpoint not reported
  • MAD Cohort 2: endpoint not reported
  • MAD Cohort 3: endpoint not reported